MedTrace Logo

Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress

NCT05344625 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2024-01-24

No results posted yet for this study

Summary

The present study will investigate if ketamine-assisted psychotherapy during palliative radiation therapy is safe, feasible, and effective at reducing psychological distress.

Conditions

  • Cancer-related Problem/Condition
  • Depressive Symptoms
  • Anxiety Disorders

Interventions

DRUG

Ketamine 100 MG/ML

Ketamine Assisted Psychotherapy

Sponsors & Collaborators

  • Northwell Health

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2024-03-15
Completion
2024-03-15
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05344625 on ClinicalTrials.gov